Article ISI
JOURNAL OF THORACIC ONCOLOGY  (2021)

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Lee, Jong-Seok; Audigier-Valette, Clarisse; Linardou, Helena; Otterson, Gregory A.; Nishio, Makoto; Jimenez, Emmanuel de la Mora; Lesniewski-Kmak, Krysztof; Albert, Istvan; Ahmed, Samreen; Penrod, John R.; Blum, Steven, I; Nathan, Faith E.; Sun, Xiaowu; Moreno-Koehler, Alejandro; Taylor, Fiona; et. al.

Abstract

Introduction: In CheckMate 227 (NCT02477826), patients with treatment-naive stage IV or recurrent NSCLC and 1% or greater tumor programmed death ligand 1 expression had significantly improved overall survival with nivolumab plus ipilimumab versus chemotherapy. We present the patient-reported outcomes (PROs).

Más información

Título según WOS: First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
Título de la Revista: JOURNAL OF THORACIC ONCOLOGY
Volumen: 16
Número: 4
Editorial: Elsevier Science Inc.
Fecha de publicación: 2021
Página de inicio: 665
Página final: 676
DOI:

10.1016/J.JTHO.2020.12.019
Notas: ISI